CRP levels after starting steroids for giant cell arteritis
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study measures how C-reactive protein (CRP), a marker of inflammation, changes in people with giant cell arteritis after they start taking steroids. It aims to understand the body's response to treatment and help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been newly diagnosed with giant cell arteritis (GCA).
- You are hospitalized and starting steroid treatment.
- You are covered by a social security or health insurance plan.
- You can give your informed consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks patients with giant cell arteritis (GCA, a blood vessel inflammation affecting older adults) who are in remission and tapering their steroid medications. Researchers will monitor disease activity through blood tests and patient questionnaires to understand if their condition stays stable as they reduce treatment.
This trial tests if a shorter course of the steroid prednisone, combined with tocilizumab, works as well as a longer course for giant cell arteritis. You must already be starting tocilizumab and taking at least 20 mg of prednisone daily.
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
This study is for people with giant cell arteritis (GCA), a condition where blood vessels become inflamed. It tests a drug called rituximab to see if it can help by targeting special immune cells (B cells). The study uses scans to look at inflammation in the large blood vessels. You must have active GCA in the large vessels (shown by a scan in the last 4 weeks), be over 50, and start treatment with steroids alone (no other immune-suppressing drugs yet). You cannot have been on steroids for more than 4 weeks before joining.
This study uses ultrasound, a biopsy of the temple artery, and blood tests to improve how giant cell arteritis (GCA) is diagnosed, monitored, and predicted. It may help doctors find better ways to manage this condition.
This trial is for people newly diagnosed with giant cell arteritis (GCA) who have a 'halo' sign on their temporal artery ultrasound. It will study how quickly the halo disappears after starting steroid treatment, helping doctors understand the best way to use steroids for this condition.
Hear when a new Giant Cell Arteritis (GCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.